Purpose of review Chronic nonbacterial osteomyelitis encompasses a spectrum of sterile bony inflammatory lesions that are incompletely understood and not well known in the otolaryngology community.
INTRODUCTION
The term 'chronic nonbacterial osteomyelitis (CNO)' has emerged as a global term to describe a spectrum of autoinflammatory bone diseases, including chronic recurrent multifocal osteomyelitis (CRMO), synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome, diffuse sclerosing osteitis (DSO), and others [1 & ,2]. First described in 1972 and termed 'chronic symmetric osteomyelitis' at that time, subsequent insights into the pathogenesis and variable clinical presentations have led to the adoption by many authors of CNO as current, preferred terminology when speaking generically about this continuum of disease processes [1 & ]. Three clinical patterns have been described as follows: first, a resolving course, which terminates within 6 months of onset; second, a persistent course, which remains for greater than 6 months after onset; and third, a multifocal and recurrent course, with multiple lesions and multiple relapses. CNO most commonly affects the metaphyses of long bones, with the clavicle being the most frequently affected, followed by bones in the lower extremities [3] . Involvement of the craniofacial skeleton is well described, but less common, and typically manifests in the mandible [2, 4] .
CNO, and many of the individual disease entities and syndromes comprising therein, remains largely a diagnosis of exclusion with no universally agreed-upon diagnostic criteria. In 2000, Beretta-Piccoli et al. [5] proposed that a diagnosis of CRMO could be made if three criteria were fulfilled: first, disease course of at least 3-month duration; second, biopsy evidence of chronic bone inflammation with exclusion of other diseases; and third, failure to cultivate an organism. In 1994, Khan et al. [6] proposed a set of inclusion and exclusion criteria that are used by some physicians to aid in diagnosis, but throughout much of the literature CNO remains, as stated by Stern and Ferguson [1 & ], '. . .a diagnosis of exclusion established by the clinical presentation, imaging studies, and a culture-negative bone biopsy.' These criteria are given as follows (reproduced from [6] ):
(1) Inclusion (a) BoneAEjoint involvement associated with palmoplantar pustulosis and psoriasis; (b) BoneAEjoint involvement associated with acne; (c) Isolated sterile (exception: growth of Propionibacterium acnes) hyperostosis/osteitis (adults); (d) Chronic recurrent multifocal osteomyelitis (children); (e) BoneAEjoint involvement associated with chronic bowel disease. 
REVIEW
Given CNO describes a spectrum of conditions with clinical and etiologic similarities, we will review these entities in terms of pathogenesis, immunobiology, diagnostic workup, and treatment. ] published an interventional study investigating the effect of a 16-week course of azithromycin on SAPHO both in patients with culture-positive and culture-negative osteitic lesions. Erythrocyte sedimentation rate (ESR) and MRI imaging were measured at pretreatment baseline, at the conclusion of antibiotic therapy, and at 12-week postantibiotic completion. Although both MRI and ESR scores were significantly decreased from baseline after 16 weeks of azithromycin, this effect was lost by 12-week postantibiotic completion. It is hypothesized that the observed improvement was due to anti-inflammatory properties of azithromycin, rather than an antimicrobial action because it led to improvement even in culture-negative patients, and because the effect was not sustained after completion of treatment, as would be expected if the infection were the under-
Pathogenesis
Many authors contend P. acnes is a trigger of CNO rather than a infectious causative agent, although this is a somewhat controversial aspect of the literature. This uncertainty led to P. acnes' inclusion on proposed diagnostic schema (see the list given under the Introduction section) as an exception to the necessity for culture-negative biopsy when considering the diagnosis of CNO [4, 8] . The mechanism of P. acnes triggering CNO is a matter of ongoing investigation, although it is known that P. acnes upregulates inflammatory cytokines such as interleukin-1, interleukin-8, and tumor necrosis factor alpha (TNF-a), and these cytokines and pathways are some of the mechanisms being investigated regarding the underlying mechanism of CNO [9] .
Immunology
Dysfunction of the innate immune system is a hallmark of many autoinflammatory diseases, including the spectrum of CNO. The precise genetic and immunologic mechanisms involved in CNO (including CRMO and SAPHO) are currently not well understood and are being actively investigated. Interleukin-1 pathway is a potential target for treatment, as successes in interleukin-1 blockade have been achieved in other autoinflammatory disorders felt to be mechanistically similar to CNO such as Majeed syndrome [9] . Majeed syndrome is a very rare germ-line mutation in the LPIN2 gene described in three families in the Middle East; the resultant defective lipin-2 protein clinically manifests as the combination of CRMO, dyserythropoietic anemia, and skin bumps and blistering. Although results are less consistent in CNO, similarities between Majeed and CNO, in particular SAPHO, continue to fuel ongoing research efforts.
Recent research suggests involvement of the interleukin-10 pathway as another potential target.
KEY POINTS
CNO represents a spectrum of sterile inflammatory bony lesions.
Several inflammatory cytokine pathways are being investigated as possible mechanisms, such as interleukin-1, interleukin-10, interleukin-8, interleukin-18, and TNF-a.
NSAIDs remain first-line treatment for symptoms of CNO, with surgery reserved for refractory, severe cases.
In 2002, Golla et al. [10] described a possible genetic locus for susceptibility to CRMO on chromosome 18, 18q21.3-18q22, and Hoffmann et al. [11] identified a promoter polymorphism for interleukin-10, a 1082G or G allele causing interleukin-10 pathway dysregulation and increased inflammatory response, albeit without objective, measurable increase in interleukin-10 levels in circulating monocytes. Interleukin-10 expression in circulating monocytes was shown to be decreased in CNO lymphocytes by the same investigators, and is associated with decreased extracellular-signal-regulated kinase1/2 and H3S10p, the latter being an activator of expression. These authors suggested that epigenetic effects may be responsible, and hypothesized that mitogenactivated protein kinase signaling impairment leads to global proinflammatory and anti-inflammatory cytokine imbalance, which may contribute to the development of CNO [12] .
Also, associated with CNO are high levels of interleukin-8, interleukin-18, and TNF-a, all of which are proinflammatory cytokines [13 && ,14]. TNF-a has been described as particularly important in mandibular CNO or SAPHO, and success has been achieved with TNF-a inhibitors, although clinical improvement has been demonstrated with combined corticosteroid or bisphosphonate use in mandibular CNO as well [15] [16] [17] [18] . Search for a common autoinflammatory marker is ongoing, and in a series of 90 SAPHO patients, the most common elevated autoantibody was found in only 15.5% of the patients [13 && ].
Diagnosis
Various diagnostic schemas have been proposed for CNO (see the list given under the Introduction section), based on clinical and radiographic findings. In addition to clinical presentation and imaging, a biopsy of the inflammatory lesion is required to establish the absence of infection. In a 2011 surveillance study of all pediatric and orthopaedic hospitals in Germany, the incidence of CNO was estimated at 0.4 per 100 000 children, and a slight female predominance was observed (67% of patients) [19] .
Presenting symptoms are frequently vague, with insidious bone pain of 6-month duration being the most frequently described. In one series from the United Kingdom, the mean age of onset was 11 years old (range 2-16 years) [3] . Subsequent imaging is guided by the patients' symptoms, with confirmatory biopsy indicated of any discrete lesions identified by imaging.
Imaging
Given the oft-vague presenting symptoms, typically pain, initial choice of imaging is based on the location involved. Standard radiographs are an appropriate first choice in most anatomic locations, although they are less sensitive than other imaging modalities. For suspected mandibular lesions, orthopantomograms or four-view mandible roentgenograms are effective, depending on availability. In one early series, such radiographic methods were found to be inferior to computed tomography (CT), MRI, or Technetium-99 scintigraphy (Tc 99 ) for detection of lesions, but the authors concluded that these more sensitive modalities were best reserved for persistent symptoms or high clinical suspicion due to increased radiation exposure and/or cost associated with them [20] .
Once a suspicious lesion is identified with a concurrent suspicious clinical history, whole-body imaging has been recommended to search for occult additional lesions. Historically, this was accomplished with Tc 99 , although recent series have demonstrated superior sensitivity with whole-body MRI [21, 22] . From a meta-analysis of all causes of chronic osteomyelitis, PET with CT appears to have the overall highest sensitivity and specificity, although this study did not perform subgroup analysis regarding sterile vs. infectious causes. The same issues regarding cost and increased radiation exposure, in addition to potential allergic reactions to reagents, must be considered with PET or CT [22] .
Treatment
NSAIDs, such as naproxen, have been the traditional mainstay of treatment for CNO. There is some variability reported, however, with NSAIDs being less effective in the patients with relapsing CNO vs. nonrelapsing (42% vs. 100%, respectively) [1 & ]. The type of NSAID also likely plays a role, with indomethacin being perhaps more effective in relapsing patients when compared with naproxen, although more side-effects have been reported with indomethacin. It is these failures of conventional NSAID treatment that have been the focus of recent studies. Because of the rarity of the condition, all are small, and most retrospective. Disease-modifying antirheumatic medications (DMARDs), such as methotrexate and sulfasalazine, as well as corticosteroids, have been employed in small series with variable results. TNF-a has been identified as a promising therapeutic target, and TNF-a antagonists have induced clinical and radiographic remission of CNO in several small series [1 & ,23,24
&&
]. Surgical treatment may also be necessary, particularly in refractory cases in locations amenable to resection, such as the mandible. In a small prospective recent series, clinical improvement was achieved with decortication and curettage of the affected areas of mandible [25] . These authors noted, importantly, flares of the disease may still be possible after such a treatment, as the underlying pathophysiologic process is still in effect. Regarding the degree of surgery, a conservative approach is typically employed (decortication as opposed to segmental mandibulectomy or maxillectomy) to minimize postoperative dysfunction. This approach has stood the test of time since initially reported by Obwegeser in the 1960s [26] . Recurrence rates after decortication are variable and can be as high as 50% in some series [25] . The proposed mechanism of benefit centers around the increased local blood flow after decortication and removal of the inflammatory bony nidus, potentially favoring healing and bony regrowth.
CONCLUSION
CNO encompasses a spectrum of autoinflammatory sterile bone lesions that may include associated systemic and dermatologic manifestations. Diagnosis is established on the basis of clinical and radiologic findings, coupled with a culture-negative biopsy. The immunologic disturbances leading to these disease states are areas of active ongoing research. NSAIDs are first-line treatment, although additional anti-inflammatory medications such as glucocorticoids or DMARDs may be required for refractory cases. Surgical treatment options exist as well, although may be limited because of the anatomic location of some lesions.
